Harrow
Lauren Silvernail possesses extensive experience in corporate governance and finance, serving as a member of the Board of Directors for multiple companies including Harrow, Harpoon Therapeutics, and Nicox, where responsibilities also include leadership roles such as Chair of the Audit and Nominating Committees. In executive positions, Lauren has held the roles of Chief Financial Officer and Executive Vice President of Corporate Development at Evolus, as well as Chief Business Officer and Chief Financial Officer at Revance Therapeutics. Academically, Lauren earned an MBA in Finance from UCLA Anderson School of Management and a BA in Biophysics from the University of California, Berkeley.
This person is not in any teams
This person is not in any offices
Harrow
2 followers
Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic‑focused pharmaceutical compounding business, which also serves as a mail-order pharmacy licensed to ship prescription medications in all 50 states. Harrow has non-controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc., companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in four late-stage drug candidates being developed by Surface and Melt.